BHC

Lenar Aimee J.

Known title: EVP, US PharmaCIK: 0002029927

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 12, 2026

BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.

this person other insiders at BHC

Transaction History

BHC▼ Sell$259K
BHC▼ Sell$25K
BHC▼ Sell$114K
BHC▼ Sell$106K
BHC▲ Buy$0
BHC▲ Buy$0
BHC▼ Sell$146K
BHC▲ Buy$0
BHC▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.